FDA pom zoo ibrutinib rau kev kho mob chronic graft-vsus-host disease (cGVHD) hauv menyuam yaus

Thaum Lub Yim Hli 24, 2022, US Food and Drug Administration (FDA) tau pom zoo ibrutinib rau kev kho mob ntawm cov menyuam yaus hnub nyoog qis dua 1 xyoos nrog tus kab mob chronic graft-vsus-host disease (cGVHD) uas tau txais tom qab tsis ua haujlwm ntawm 1- lossis ntau kab. kev kho mob.Cov lus pom zoo yog feem ntau yog rau cov neeg mob menyuam yaus, nrog rau tag nrho cov lus teb ntawm 60% ntawm lub lim tiam 25, thiab cov tshuaj formulations muaj xws li tshuaj ntsiav, ntsiav tshuaj thiab qhov ncauj ncua kev kawm ntawv.

Ibrutinib, BTK inhibitor co-tsim los ntawm Pharmacyclics/Johnson & Johnson, yog kinase inhibitor yav dhau los tau pom zoo rau kev kho mob ntawm cov qog ntshav qog ntshav qog ntshav ntev nrog rau cov qog ntshav qog ntshav thiab lwm yam kab mob.

Suntech tsom rau kev txhim kho thiab tsim cov tshuaj intermediates thiab APIs siv ntsuab technology.Tam sim no, peb lub tuam txhab tau tsim peb cov khoom nruab nrab ntawm ibrutinib suav nrog C AS: 143900-44-1 , C AS: 330792-70-6 , C AS: 330786-24-8 , tag nrho cov uas tau ua lag luam hauv GMP factories ntau lawm .Ntawm lawv, qhov nruab nrab ntawm C AS: 143900-44-1 yog tsim los ntawm chemical-enzymatic technology, uas muaj qhov zoo ntawm kev tiv thaiv ib puag ncig ntsuab, tsis tshua muaj nqi thiab zoo.Txais tos rau sab laj thiab koom tes!